Sélectionner une page
Logo Company

OSIVAX

Alexandre LE VERT

Chairman and CoFounder

Who are we?

OSIVAX is a biotech start-up based in France (Lyon), which develops CD8 T-cell inducing vaccines thanks to its technology platform, oligoDOM®. OSIVAX’ lead candidate is an influenza vaccine that is about to start a phase I clinical trial:
• Despite a $4bn Flu vaccine market, influenza is still devastating (56,000 deaths in the US only in 2014-15)
• An alternative path to improve Flu vaccine efficacy was recently described: cellular immune response against Influenza NucleoProtein-NP)
• Osivax has a best-in-class product (OVX836) with a blockbuster potential: OVX836 demonstrated 100% protection against multiple Flu strains in mice & ferrets. Combined with seasonal Flu vaccines OVX836 has a blockbuster potential (>$1B/yr)
• OVX836 is about to enter a phase I clinical trial, with a licensure expected in 2022.